HOTH shows severe financial deterioration with R&D expenses surging 83% to $5.9M, net losses widening 52% to -$12.5M, and auditors expressing substantial doubt about the company's ability to continue as a going concern.
The combination of dramatically worsening financial performance and the addition of going concern qualification creates significant risk for investors. The company's cash position declined to $6.2M while burn rate accelerated substantially, raising immediate questions about funding runway and survival without additional capital raises that would likely dilute existing shareholders.
HOTH's financials show across-the-board deterioration with R&D expenses nearly doubling to $5.9M driving net losses 52% higher to -$12.5M and operating cash flow worsening 41% to -$9.8M. The balance sheet weakened with cash declining 11% to $6.2M, current liabilities surging 75% to $1.5M, and stockholders' equity falling 11% to $6.2M. This combination of accelerating cash burn, declining cash reserves, and rising liabilities signals potential liquidity stress for this early-stage biotech company.
R&D investment increased 83% — signals commitment to future product development, though near-term margin impact.
Current liabilities surged 74.8% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 74.2% — significant increase in debt or obligations, assess impact on financial flexibility.
Net income declined 52.3% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow fell 40.5% — earnings quality concerns; investigate working capital changes and non-cash items.
Cash decreased 11.2% — monitor burn rate and upcoming capital needs.
Equity decreased 10.6% — buybacks or losses reducing book value, monitor solvency ratios.
Current assets declined 10.2% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →